New combo therapy aims to supercharge immune cells against tough melanoma

NCT ID NCT06940739

Recruiting now Disease control Sponsor: Iovance Biotherapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests a new drug (IOV-3001) designed to boost immune cells in people with advanced melanoma that has not responded to prior treatments. About 42 adults will receive the drug alongside a personalized cell therapy called lifileucel. The main goals are to check safety and find the best dose, while also measuring how the drug behaves in the body and affects the immune system.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma ocular melanoma uveal melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC MELANOMA OCULAR MELANOMA UNRESECTABLE MELANOMA

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Greenslopes Private Hospital
RECRUITING

Greenslopes, Queensland, 4120, Australia
Hollywood Private Hospital Ramsay
RECRUITING

Nedlands, Western Australia, 6009, Australia
SCRI Oncology Partners- Denver
RECRUITING

Denver, Colorado, 80218, United States
Sarah Cannon Research Institute
RECRUITING

Nashville, Tennessee, 37203, United States
UNC Hospitals, The University of North Carolina at Chapel Hill
RECRUITING

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.